Cosmos Holdings Inc. - COSM STOCK NEWS

Cosmos Holdings (Nasdaq: COSM) announces the launch of Prostatium, a proprietary supplement aimed at enhancing prostate health and preventing symptoms of Benign Prostate Hyperplasia (BPH). With about 30 million men affected worldwide, Prostatium includes proven ingredients like Saw Palmetto and Lycopene, manufactured under stringent standards. The company aims to expand its product reach across Europe and North America while tapping into the growing demand for high-quality nutraceuticals. CEO Greg Siokas highlighted the importance of this unique formulation developed by their R&D team.

Cosmos Holdings (NASDAQ:COSM) announced its participation in the Virtual Growth Conference hosted by Maxim Group LLC on March 28-30, 2022, from 9:00 a.m. to 5:00 p.m. ET. Investors can access the Company's pre-recorded presentation over these three days. The event will cover various sectors, including Biotech, Clean Energy, and Healthcare, featuring presentations, fireside chats, and discussions with CEOs. Cosmos Holdings is an international pharmaceutical company specializing in nutraceuticals and distributing pharmaceuticals across Europe, Asia, and North America.

Cosmos Holdings (Nasdaq: COSM) announced significant milestones in a shareholder letter dated March 23, 2022. The company successfully uplisted to the Nasdaq and raised $6 million. Their 2021 initiatives included launching new nutraceutical products and establishing distribution deals on Amazon UK and Alibaba's Tmall. Cosmos aims for a 15-20% revenue growth in 2022, targeting $65 million while improving gross margins to 18%. The global nutraceutical market is projected to grow from $352.9 billion in 2021 to $658.1 billion by 2028, presenting a robust landscape for the company.

Cosmos Holdings, Inc. (Nasdaq: COSM) has successfully closed a private placement offering, raising approximately $6 million by selling 6,000 shares of Series A Convertible Preferred Stock and 2,000,000 warrants. Each preferred share was priced at $1,000, reflecting its stated value. The new capital will enhance the company's financial position, while the holders of preferred stock have rights to convert their shares into common stock at an attractive conversion price. The warrants, priced at $3.30 per share, are exercisable over the next five and a half years.

Cosmos Holdings (COSM) announced a private placement to raise approximately $6 million through the sale of 6,000 shares of Series A Convertible Preferred Stock and warrants for 2 million common shares. Each preferred share is priced at $1,000. The offering coincides with Cosmos's successful listing on the Nasdaq Capital Market. CEO Greg Siokas emphasized the company's scalable business model and plans for global expansion of its nutraceuticals and third-party pharmaceuticals. The company converted over $11 million in debt to equity, strengthening its balance sheet for future growth.

Cosmos Holdings (COSM) has commenced efforts toward a direct listing on the Nasdaq Capital Markets. On September 15, 2021, the Board approved a private offering of 5,000,000 shares of Series A Preferred Stock to a private investor for $5 million. Shareholders holding 51% of voting power approved the Offering on December 17, 2021. The Series A Preferred Stock is convertible into common stock at $4.00 or 80% of the average VWAP prior to uplisting, with a floor at $3.00. This move aims to enhance liquidity and expand the company's market presence.

Cosmos Holdings (OTCQX: COSM) reported its third quarter financial results for 2021, highlighting positive adjusted net income and EBITDA. The company focused on debt reduction, converting $10.2 million of debt to equity, and secured an investment commitment of approximately $5.5 million from Ault Global Holdings. Cosmos expanded its distribution network, entering an exclusive agreement in Germany and Austria and launching products on Alibaba's Tmall Global. Working capital rose to $6.9 million, and shareholder equity increased to $4.7 million, showcasing financial improvement.

Cosmos Holdings (COSM) has successfully integrated SSI SCHAEFER's A-Frame Automated Robotic Picking System into its logistics center, CosmoFarm, enhancing order processing capabilities. This system can manage up to 40,000 products per hour and is designed to handle various packaging shapes and sizes. CEO Greg Siokas emphasized that this automation supports the company’s growth ambitions by improving service quality and productivity. CosmoFarm, based in Athens, Greece, is licensed for wholesale pharmaceutical distribution, serving over 1,130 pharmacies.